September 13, 2021

SomaLogic, UPMC partner on protein study

By

BOULDER — SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public this month in a merger with a special purpose acquisition company, and the University of Pittsburgh Medical Center are joining forces to study how proteins may be used in clinical care. 

SomaLogic develops platforms to read thousands of proteins in a patient’s blood or urine sample that may signal illnesses or future health conditions and suggest potential treatments via machine learning.

“As part of the agreement, UPMC and SomaLogic will establish a collaboration to promote the use of proteomic data in building healthier communities, improving patient care and reducing healthcare costs,” SomaLogic said.

“Working with UPMC, a leading innovator in healthcare, allows us to evaluate together the value of proteomics as a tool for precision medicine and a means for clinicians in the future to more accurately assess risk and tailor care for their patients,” SomaLogic CEO Roy Smythe said in a prepared statement. 

© 2021 BizWest Media LLC

BOULDER — SomaLogic Inc. (Nasdaq: SLGC), a Boulder-based biotechnology company that went public this month in a merger with a special purpose acquisition company, and the University of Pittsburgh Medical Center are joining forces to study how proteins may be used in clinical care. 

SomaLogic develops platforms to read thousands of proteins in a patient’s blood or urine sample that may signal illnesses or future health conditions and suggest potential treatments via machine learning.

“As part of the agreement, UPMC and SomaLogic will establish a collaboration to promote the use of proteomic data in building healthier communities, improving patient care and…

Tommy Wood
Categories: Boulder Life Sciences SomaLogic Inc.
Sign up for BizWest Daily Alerts